An APOE Result on a Consumer DNA Report

Your ancestry kit came back with a line about APOE, or a 23andMe Alzheimer's report flagged an e4 variant, and somewhere between reading that and reaching the health questions on a life insurance form the two became tangled together in your head. Here is the part that takes the pressure off first: a UK life insurer cannot ask you for an APOE result, and you do not have to offer it. An APOE variant from a shop-bought genetic test is a predictive result, and predictive genetic results are kept off life insurance applications by a long-standing agreement between government and the insurance industry.

The APOE gene comes in a few common versions. One of them, known as e4, is associated with a raised chance of developing late-onset Alzheimer's disease, and that is the line your report is describing. It is worth being exact about what it means, because the wording on a consumer report often reads far more like a verdict than the science supports. An APOE e4 result is a susceptibility variant. It shifts the odds. It is not a diagnosis, and it is not a certainty.

So the report that unsettled you sits outside what a life insurer is allowed to ask about, and the variant it describes is not the same thing as having the disease. Both of those matter, and the rest of this page takes them one at a time: what the APOE line actually tells you, why it is protected, and the narrow set of things about your own health that you would still have to answer honestly.

The short answer: they cannot ask, and you need not tell

UK life insurers agree not to ask for or take into account the result of a predictive genetic test. That agreement is set out in the Code on Genetic Testing and Insurance, made between HM Government and the Association of British Insurers. It is not a law you can be prosecuted under, but the major insurers commit to it, and it governs how a life, critical illness or income protection application may treat genetic information.

An APOE result from a 23andMe or ancestry-style kit is squarely a predictive genetic test result. You had no symptoms; the kit told you something about a future probability. That is exactly the category the Code keeps off the form. The insurer will not ask for it, and you are not expected to disclose it, even though the same application will ask a good deal about your own health and your family's.

This is the same principle that keeps a cancer-risk gene off an application. If you have read about the way a BRCA result is one insurers cannot ask you for, the logic for APOE is identical: a predictive result about a disease you do not have is not something the underwriter gets to see.

What the APOE line on your report actually says

APOE — apolipoprotein E — is a gene everyone carries, in one of a small number of common forms. The version labelled e4 is the one associated with a higher chance of late-onset Alzheimer's disease, the form of dementia that typically appears after 65. Carrying one copy raises the chance compared with the most common version; carrying two copies raises it further. That is the whole of what the report is telling you, and it is easy to over-read.

Two things temper it. First, it is a probability, not a mechanism that switches the disease on. Plenty of people who carry e4 live long lives with no dementia at all, and plenty of people who develop Alzheimer's never carried e4. Second, age is by a wide margin the strongest driver of late-onset Alzheimer's risk, and other factors that you can act on — blood pressure, smoking, physical activity, hearing, head injury — sit alongside genetics rather than beneath it. A single gene variant is one input among many.

A consumer report also cannot tell you when, or whether, or how severely. It is not a clinical assessment, it was not ordered by a doctor who knows your history, and it comes with none of the counselling that a memory clinic or a genetics service would wrap around the same information. If the line has genuinely frightened you, the useful next step is a GP conversation, not an insurance decision.

Why an APOE result counts as a predictive test

The Code draws a line that is worth understanding, because it decides everything. A predictive genetic test looks at someone with no symptoms and estimates a future risk. A diagnostic genetic test is done to explain a condition a person already has, or is showing signs of. The two are treated completely differently.

Predictive results are protected. Diagnostic results are part of ordinary medical history, because at that point they are describing an illness you actually have, and insurers have always been able to ask about illnesses you have. An APOE result from an ancestry kit is predictive by definition: you sent off saliva out of curiosity, not because a doctor was investigating memory loss. Nothing about the way you obtained it, or the fact that a private company processed it, changes that classification. It is a predictive result, and it stays off the application.

The one exception, and why APOE is not it

There is exactly one predictive genetic result a UK life insurer is currently allowed to ask about, and it is Huntington's disease, and only where the total life cover applied for is above a set threshold. Below that amount, even a Huntington's result is not askable. Every other predictive result, APOE included, is off limits at any level of cover.

Source: Code on Genetic Testing and Insurance, HM Government (Department of Health and Social Care) and the Association of British Insurers, 2018. The single approved predictive test is Huntington's disease for life insurance above £500,000 of cover.

APOE does not appear on that list, and there is no separate route by which a dementia-risk variant becomes askable. The same holds for critical illness and income protection: the Code covers those products too, each with its own financial limits, and no test is currently approved for use with them at all. So whichever of these products you are applying for, an APOE result is not part of the conversation.

What you would still have to answer honestly

Protection of the gene result does not switch off the rest of the form. You still have to answer, accurately and with reasonable care, the questions the insurer does ask — and some of those can touch the same territory from a different direction.

If you have actually had a memory problem looked into by a doctor — a referral, a cognitive assessment, a brain scan, a clinic appointment — that is medical history, and it is disclosable if you are asked about investigations or symptoms. The APOE result stays protected; the clinical episode does not, because it is describing something that happened to your health rather than a probability printed by a testing company. The distinction is between a gene report you bought and a doctor's involvement you sought.

Where an investigation is still in progress rather than finished, the position needs its own care, and we set it out in what has to be said when you are mid-investigation and mid-application at once. The short version is that pending investigations are disclosable if the form asks, and that timing an application to get ahead of a result works against you rather than for you.

A favourable result is a different case

The Code runs one way. An unfavourable predictive result cannot be used against you, and you are under no obligation to hand one over. But a favourable predictive result — one that rules out a risk your family history would otherwise suggest — is something you are allowed to volunteer if it helps you. APOE e4 is not that kind of result, so there is nothing here to gain by sharing it. But the mechanism is worth knowing, and it is the whole point of telling an insurer you tested negative in a family with a known fault: you can offer good news, and they cannot demand bad.

If you already hold a policy and are wondering whether a later test could unravel it, that is a common and reasonable worry with its own answer, covered in what happens if you have a genetic test after the policy started. A predictive test taken after cover is in force does not reach back and affect a policy that is already running.

Family history is not the same as a gene test

It is easy to assume that because the APOE result is protected, anything to do with dementia in your family is protected too. It is not. Insurers are allowed to ask about family history — whether your parents or siblings had certain conditions, and at what age — and a family history of dementia can be one of the things they weigh. That question is asked and answered on its own terms, entirely separately from any gene test you may have taken.

The reassuring part is how weak a single relative's dementia usually is as a signal once age is accounted for, and how much the raw fact matters less than the detail. If this is really a question about what two parents or a close relative mean for your own odds, the more useful place to start is the arithmetic of it, which we work through in what it actually means when both parents died before 60. Family history colours an application; on its own it rarely decides one.

None of this needs to stop you moving forward. If the point of reading this was to find out whether the APOE line blocks you, it does not: you can get life insurance quotes and apply on the basis of your health and your family history, with the gene result staying out of it entirely. If you want to see how the whole subject fits together, our guide to family history, inherited risk and the odds maps the rest.

Scotland and Northern Ireland

The insurance position is the same across the United Kingdom. The Code on Genetic Testing and Insurance is a UK-wide agreement, and the Consumer Insurance (Disclosure and Representations) Act 2012, which sets the standard of care for answering an insurer's questions, applies throughout the UK. So an APOE result is equally off limits to an insurer in Edinburgh, Belfast, Cardiff or Manchester, and the duty to answer honestly about your own health is the same everywhere.

What differs is the clinical machinery around it. NHS genetics services and memory clinics are organised separately in Scotland, Wales and Northern Ireland, so a referral pathway and the wait for it can look different depending on where you live. That changes how you would be assessed by a doctor, not how you would be treated by an underwriter. If a consumer report has genuinely worried you, your own GP is the right door regardless of nation.

Frequently asked questions

Can a UK insurer ask about my APOE result?

No. An APOE variant reported by a consumer DNA kit is a predictive genetic result, and the Code on Genetic Testing and Insurance keeps predictive results off life insurance applications. Huntington's disease above £500,000 of cover is the single listed exception, and APOE is not on that list.

Does APOE e4 mean I will get Alzheimer's?

No. It is a susceptibility variant that shifts risk rather than a diagnosis or a certainty. Many people carrying it never develop dementia, and many people who develop dementia do not carry it. Age remains by far the strongest risk factor, and other health factors matter too.

Should I tell an insurer anyway, to be safe?

There is no need, and volunteering an unfavourable predictive result is not something the Code expects of you. You must still answer the questions asked about your own symptoms, diagnoses and treatment. If a memory problem has been investigated by a doctor, that is medical history rather than a gene result.